Blue Earth Therapeutics is an Oxford, UK–based clinical-stage company developing next-generation targeted radiopharmaceuticals, with an emerging pipeline initially focused on prostate cancer. The company is advancing clinical-stage PSMA-targeted radioligand therapies and aims to innovate on current radiotherapeutic technologies. Blue Earth was incubated within the Bracco family of companies and leverages management expertise across radiopharmaceutical and oncology drug development. David Gauden serves as CEO and leads the company’s efforts to rapidly advance new targeted therapies for serious diseases. The company’s immediate plan, supported by the new financing, is to further advance its clinical programs. No operating metrics (revenue/users) were disclosed in the article.

Total raised

$77M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2024